Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.65 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.48 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.48 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775939 | 0.90 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL13617046 | 0.89 | MAP2K1 (0.82) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL1774521 | 0.80 | MAP2K1 (0.80) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL14205758 | 0.80 | MAP2K1 (0.68) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL14205847 | 0.79 | MAP2K1 (0.65) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL14205760 | 0.79 | MAP2K1 (0.67) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL13616884 | 0.79 | MAP2K1 (0.67) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL1775958 | 0.79 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL1777951 | 0.79 | MAP2K1 (0.65) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL391286 | 0.78 | MAP2K1 (0.59) | MAP2K1MAP2K2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2113500-A1 | MAPK/ERK kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| WO-2008055236-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | WO | disclosed |